Working… Menu

Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02992964
Recruitment Status : Active, not recruiting
First Posted : December 14, 2016
Last Update Posted : February 15, 2021
Bristol-Myers Squibb
Information provided by (Responsible Party):
Daniel Morgenstern, The Hospital for Sick Children

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : September 2021